Pfizer Zeldox Prolongs QT Interval 30 To 60 Msec In 11.6% Of Patients
The oral formulation of Pfizer's Zeldox is associated with a QT prolongation of 30 to 60 milliseconds in 11.6% of patients, an update of Swedish labeling for the atypical antipsychotic states.
You may also be interested in...
Pfizer expects an "approvable" action from FDA in September to set up a final round of negotiations over labeling for the antipsychotic Zeldox, Pfizer Global R&D President John Niblack indicated during a July 27 investor conference call.
The QTc prolongation associated with Pfizer's antipsychotic Zeldox does not lead to the same clinical events as seen with Abbott/Lundbeck's antipsychotic Serlect, Pfizer told the Psychopharmacological Drugs Advisory Committee July 19.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011